Lisata Therapeutics Inc. (LSTA) Next Earnings Date & Expected ±12.5% Move

Per the Roarable RQD rating, LSTA carries an RQD Score of 29 and a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are: Fundamental Cash Engine at 8/20 (ROIC -35%; FCF yield 0%); Whale 13F Flow at 3/20 (institutional accumulation and options positioning); Insider Conviction at 3/20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit at 7/20 (Beta 1.0; sector sensitivity); and Forensic Balance Sheet at 8/20 (Altman Z 2.5; Piotroski F 3/9; Debt/Equity 0.5). Taken together, the pillars indicate weak cash generation, weak institutional and insider signals, and a balance sheet the rating classifies as forensically risky. For a prospective investor, the rating points to downside risk rather than a value or growth case. Upside would require a reversal in cash burn and a sustained change in institutional and insider behavior, neither of which the source data demonstrates.

Per the SEC financials, revenue declined from $1.0M in FY 2024 to $0.2M in FY 2025, while net losses narrowed from $-20.0M to $-17.0M across the same period. Per the market data, operating margin and net margin are each -60%, gross margin is 0%, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 3/9, with a Debt/Equity ratio of 0.5. Reported cash was $16.0M in FY 2025, against negative free cash flow of $-16.0M in the same year.

Per the recent news and catalysts section, the most recent items include:

• A report that Lisata Therapeutics won a new US patent for a pancreatic cancer drug.
• A Stocktwits report on sentiment score, message volume, participation score, and buzz level.
• A Stock Titan report referencing an SEC filing dated Oct 19, 2026.
• A GlobeNewswire report announcing a new method-of-use patent.
• A Halper Sadeh LLC investigation headline referencing whether LSTA, among other companies, is obtaining fair deals for shareholders.

All items are tagged with a YELLOW light and a MARKET WIRE impact label. Per the Butterfly Supply-Chain Graph, the supply chain is recorded as NONE and no proprietary signals are present. The investigation headline is a risk watch item, though the source data does not describe its scope or any findings.

• What are the specific products, indications, and development stage behind the patent and pancreatic cancer headlines, and do they carry a revenue path?
• What is the scope and status of the Halper Sadeh LLC investigation, and does it involve a transaction affecting shareholders?
• What is the current cash runway given FY 2025 cash of $16.0M against FCF of $-16.0M?
• Why are debt, EPS, and EV/EBITDA recorded as N/A or not available, and what is the full capital structure?
• Who holds the shares, and what are the current 13F and insider positions?